Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 7
2004 4
2005 12
2006 9
2007 11
2008 11
2009 6
2010 16
2011 10
2012 13
2013 21
2014 21
2015 19
2016 16
2017 19
2018 20
2019 11
2020 3
2021 1
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.
Lu H, George J, Eslam M, Villanueva A, Bolondi L, Reeves HL, McCain M, Chambers E, Ward C, Sartika D, Sands C, Maslen L, Lewis MR, Ramaswami R, Sharma R. Lu H, et al. Among authors: bolondi l. Liver Cancer. 2022 Jul 8;12(1):19-31. doi: 10.1159/000525911. eCollection 2023 Feb. Liver Cancer. 2022. PMID: 36872928 Free PMC article.
History of Ultrasound in Medicine from its birth to date (2022), on occasion of the 50 Years Anniversary of EFSUMB. A publication of the European Federation of Societies for Ultrasound In Medicine and Biology (EFSUMB), designed to record the historical development of medical ultrasound.
Dietrich CF, Bolondi L, Duck F, Evans DH, Ewertsen C, Fraser AG, Gilja OH, Jenssen C, Merz E, Nolsoe C, Nürnberg D, Lutz H, Piscaglia F, Saftoiu A, Vilmann P, Dong Y, Hill CRK. Dietrich CF, et al. Among authors: bolondi l. Med Ultrason. 2022 Dec 21;24(4):434-450. doi: 10.11152/mu-3757. Epub 2022 May 15. Med Ultrason. 2022. PMID: 35574917 Free article. Review.
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Kelley RK, et al. Among authors: bolondi l. ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714. ESMO Open. 2020. PMID: 32847838 Free PMC article. Clinical Trial.
Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study).
Donati G, Angeletti A, Gasperoni L, Piscaglia F, Croci Chiocchini AL, Scrivo A, Natali T, Ullo I, Guglielmo C, Simoni P, Mancini R, Bolondi L, La Manna G. Donati G, et al. Among authors: bolondi l. J Nephrol. 2021 Feb;34(1):77-88. doi: 10.1007/s40620-020-00799-w. Epub 2020 Jul 24. J Nephrol. 2021. PMID: 32710265 Free PMC article.
MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma.
Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F. Gramantieri L, et al. Among authors: bolondi l. Cancer Res. 2020 Apr 15;80(8):1720-1734. doi: 10.1158/0008-5472.CAN-19-0472. Epub 2020 Feb 3. Cancer Res. 2020. PMID: 32015093
206 results